Bristol's Abatacept, Muraglitazar To Go Before Advisory Committees In September
This article was originally published in The Pink Sheet Daily
Executive Summary
Orencia (abatacept) for moderately to severely active rheumatoid arthritis will be reviewed by FDA's Arthritis Drugs Advisory Commmittee. Pargluva (muraglitazar) will be considered by FDA's Endocrinologic & Metabolic Drugs Advisory Committee for type II diabetes mellitus.